# Efficacy and Safety of Cladribine in Combination With CAG in Newly Diagnosed Unfit Patients With AML

> **NCT04254640** · PHASE2 · UNKNOWN · sponsor: **Sun Yat-sen University** · enrollment: 34 (estimated)

## Conditions studied

- Acute Myeloid Leukemia
- Elderly Patients
- Newly Diagnosed

## Interventions

- **DRUG:** Cladribine Injection
- **DRUG:** Aclarubicin
- **DRUG:** G-CSF
- **DRUG:** cytarabine

## Key facts

- **NCT ID:** NCT04254640
- **Lead sponsor:** Sun Yat-sen University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-03-01
- **Primary completion:** 2023-06-01
- **Final completion:** 2023-12-31
- **Target enrollment:** 34 (ESTIMATED)
- **Last updated:** 2020-12-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04254640

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04254640, "Efficacy and Safety of Cladribine in Combination With CAG in Newly Diagnosed Unfit Patients With AML". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04254640. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*